{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-220087","form_type":"8-K","ticker":"CTMX","cik":"0001501989","company_name":"CytomX Therapeutics, Inc.","filed_at":"2023-08-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.121752+00:00","generated_at":"2026-06-11T04:07:51.654836+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CytomX Therapeutics regains exclusive worldwide rights to ADC CX-2029 from AbbVie","bullets":["Regained full worldwide rights to develop CX-2029, a CD71-targeting conditionally activated antibody drug conjugate.","AbbVie eligible for tiered sales royalties on CX-2029 ranging from low-to-mid single digit percentages.","CytomX to pay Seagen potential future milestones and tiered sales royalties (mid-to-high single digits) for linker payload tech.","Transition Agreement supersedes the terminated 2016 CD71 Co-Development and License Agreement with AbbVie."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-220087","json":"https://secwatch.observer/filing/0001193125-23-220087.json","markdown":"https://secwatch.observer/filing/0001193125-23-220087.md","text":"https://secwatch.observer/filing/0001193125-23-220087.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501989/000119312523220087/0001193125-23-220087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501989/000119312523220087/d489987d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T04:07:51.654836+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eaa3be82fa839c836c47d05bd5a026c78269027b","claim":"CytomX Therapeutics, Inc. entered into Transition Agreement with AbbVie Global Enterprises Ltd. valued at royalties low-to-mid single digit percentages; milestones and royalties mid-to-high single digit per (effective 2023-08-22).","evidence_excerpt":"On August 22, 2023, CytomX Therapeutics, Inc. (the “Company”) entered into a Transition Agreement (the “Transition Agreement”) with AbbVie Global Enterprises Ltd. (“AbbVie”), pursuant to which the Company regained exclusive worldwide rights to develop CX-2029, a CD71-targeting conditionally activated antibody drug conjugate.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312523220087/0001193125-23-220087-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"AbbVie Global Enterprises Ltd."},{"label":"Value","value":"royalties low-to-mid single digit percentages; milestones and royalties mid-to-high single digit per"},{"label":"Effective","value":"2023-08-22"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}